Author: BioactiveCompoundLibrary

The immuno-isolation provided by alginate encapsulation is undoubtedly the major advantage of this technology when intended for transplantation or tissue regeneration. In the case of type I diabetes, twenty-five years of preclinical studies have recently made possible significant progress in the implantation of encapsulated Langerhans islets in patients. Compared to other biopolymers, the considerable success of alginate used for microencapsulation relies upon the middle conditions required for the gelation process. Alginate salts, such as sodium-alginate, are composed of residues of Dmannuronic acid and L-guluronic acid covalently – linked in homo- or hetero-blocks, and which have a high affinity for divalent or trivalent ions. Calcium ions interact through ionic crosslinking with the carboxylate groups of monosaccharide residues allowing the formation of a three dimensional network between polymeric chains, with limited effects on cell viability. Numerous works described the antiviral activity of algal carbohydrate polymers leading to promising therapeutic applications when used either alone or associated with existing antiviral drugs. These polysaccharides are extracted from the cell walls of red, brown or green algae from which they account for more than 50% of the dry weight. Besides their considerable structural diversity, all of these polymers are negatively charged and, in most cases, present a high sulfation level. Their antiviral activities target a broad spectrum of human pathogens including enveloped viruses such as human immunodeficiency virus, herpes simplex virus, human cytomegalovirus, dengue virus, and non-enveloped viruses, such as hepatitis A virus and human papillomavirus. Based on their safety and low toxicity, marine polysaccharides are interesting solutions for limiting viral infections in clinical contexts. Although experiences using marine polymers as an orally-delivered agent have been described, only a few clinical studies have been conducted so far. The well-known anticoagulant activity of most sulfated polysaccharides, associated with their high molecular weight which is incompatible with free diffusion towards tissues, explains the obstacles to their use as natural compounds in in vivo conditions. Structural modifications by means of chemical or enzymatic processes can be requested to meet clinical constraints. Although alginate antiviral activity is described as low compared to many other marine polysaccharide compounds, we hypothesized that this property could benefit cells entrapped in calciumalginate beads for further use as implanted tissue or organ supply. For this purpose, using a simple extrusion process, we encapsulated human hepatoma-derived cells, a specific cell line which is up to now the most employed cellular model recognized for both its high permissiveness with regard to hepatitis C virus infection and its ability to produce and secrete HCV particles. The aim of this study was thus to investigate the potential protective effect of Ca-alg hydrogel encapsulating hepatic cells against HCV infection. In all cases, no infectious HCVcc particle was produced in the Torin 1 culture medium. More precisely, the non-translocation of the cleavage products RFP-NLS from cytoplasm to the nucleus showed the inability of the HCV to access the entrapped cells or to activate the HCV receptors to enter into cells. However, our previous data suggested HuH-7 cell cultures in Ca-alg beads were a relevant model for HCV infection for two reasons: i) after their encapsulation in Ca-alg beads with optimized alginate composition, isolated HuH-7 cells proliferated and reorganized into multicellular aggregates.

Similar results were observed with the RUG3 mutant. Both mutants showed reduced root growth, small stature, and growth retardation. Another complex I mutant, ndufs4, also exhibited a similar phenotype. Although approximately one-third of mitochondrial ATP production is associated with complex I, the presence of alternative NADH dehydrogenases allows the electron transport chain to bypass complex I when complex I efficiency is reduced or when plants encounter stress. Interestingly, abo5, rug3 and ndufs4 plants produced viable seeds and propagated to the next generation, whereas mterf15 showed a more severe phenotype. Homozygous mterf15 plants showed a similar BMN673 PARP inhibitor phenotype as these mutants in terms of complex I deficiency; however, seeds from homozygous mterf15 plants could not germinate, even in solid medium over three months. It is possible that mTERF15 in maternal tissues of heterozygotic mterf15 embryo may partially contribute to the developing homozygous mterf15 seeds, which is completely absent in the developing seeds of homozygous mterf15 plants. This suggests that the germination defect of mterf15 is not only due to embryo lethality but also caused by aberrant reproductive organs, especially maternal tissues. The defective maternal tissues may reduce the flow of nutrient into the endosperm and eventually cause seed lethality. Therefore, mTERF15 may have additional roles in mitochondria, as observed in other eukaryotes, during embryogenesis and seed development. Here, we identify mTERF15 as an RNA-binding protein that is required for nad2 intron 3 splicing in mitochondria. The disruption of this splicing event leads to decreased complex I activity as well as growth and developmental retardation in mterf15 mutants. Further studies of the detailed mechanism of mTERF15 are required to reveal the molecular mechanisms involved in post-transcription regulation in Arabidopsis mitochondria. Osteoporosis is a common progressive bone disease that is characterized by decreased bone mineral density and is known to increase the risk of fractures. The disequilibration of bone resorption by osteoclasts and bone formation by osteoblasts underlies the pathogenesis of osteoporosis. At-risk populations for primary osteoporosis include elderly and postmenopausal women in particular because BMD is known to decrease with age and its rate of decline is very hormonally sensitive. Estrogen may exert anti-resorptive effects on bone in part by stimulating estrogen receptors and osteoprotegerin expression in osteoblasts. Estrogen is one of many proteins that are involved in the pathogenesis of osteoporosis. Age and external factors, such as smoking, body weight and race, also influence BMD, and more recently, investigators have found that genetic factors play important roles in the pathogenesis of osteoporosis. Twin and familial studies have indicated that 60–85% of BMD variance is genetically determined.

Thus, NA14 could conceivably play a role in cytokinesis by regulating the localization and the microtubule-severing activity of spastin at the midbodies. Of possible relevance, NA14 expression is upregulated in T-cell acute lymphoblastic leukemia characterized by an amplification of 9q34 and is differentially expressed in pancreatic cancer. Several groups have shown that spastin influences microtubule dynamics in growth cones, regulating the stability of axons and axonal transport. For example, Yu et al. showed that expression of spastin regulates axon length and number of branches. They further observed that the expression of spastin positively correlates with the formation of PF-04217903 c-Met inhibitor branches and the axon size. Based on our studies in neurons, it seems reasonable to postulate that NA14 might regulate spastin. Notably, NA14 is accumulated at the centrosome during the initiation of axon formation. Spastin and related proteins such as katanin have been implicated in releasing microtubules from the centrosome during mitosis, as well as in mechanisms that regulate microtubule length in axons of postmitotic neurons. Thus, we can imagine that NA14 might trigger spastin-dependent microtubulesevering in a specific cellular location at a specific time. Further studies of the NA14-spastin interaction in vitro and in cells will be necessary to test this hypothesis. Long axons of neurons within the corticospinal tract are highly dependent on spastin function. NA14 seems to play a role in neuronal development, in particular in axon outgrowth. The accumulation of NA14 could thus regulate the recruitment and/or regulation of spastin during the development of axons. In fact, previous studies have shown that spastin acts as a microtubulesevering protein in mammalian cells, and expression of spastin mutants unable to hydrolyze ATP result in the increased formation of stable bundles of microtubules. Moreover, Rodrı´guez-Rodrı´guez et al. have shown that NA14 can create a dynamic matrix between microtubules and spastin, providing a scaffold for anchoring proteins that are involved in microtubule nucleation and axonal development. A transport role for NA14 also has precedent, since NA14 has previously been implicated in transport of the orphan receptor TPRA40/GPR175, and the interaction with NA14 is required for the effects of TPRA40/GPR175 on cell division in mouse embryos. Lastly, NA14 was identified in a high-content screen for cilia genes as a protein involved in transport/trafficking of ciliary proteins. In conclusion, our findings suggest that NA14 is involved in cytokinesis and neuronal development. NA14 could regulate the localization and activity of the microtubule-severing AAA protein spastin in the midbody as well as during axon outgrowth. The involvement of NA14 in dynamic remodeling of the microtubule cytoskeleton, in developing and adult axons, and in the regulation of spastin serves a springboard to understanding the functional roles of their interaction.

It has been proved that the viscosity associated with dietary soluble polysaccharides interferes with cholesterol absorption by directly binding cholesterol within the intestine, interfering with the diffusion of cholesterol toward the epithelial cell surface. We thus propose the reduction of cholesterol absorption in response to APS maybe attributed to its viscosity, with little regulation of genes associated with cholesterol transport. Cholesterol is mainly eliminated from the body via conversion to bile acids, and the rate-limiting enzyme of the process is cyp7a1. It has been reported that dietary soluble polysaccharides decreased serum cholesterol by altering the composition of the enterohepatic bile acid pool and increasing the fecal loss of total bile acids. In response to increased fecal bile acid excretion, there occurs a compensatory LY2109761 increase in bile acid synthesis. In this study, we reported for the first time that APS produced a marked increase in excretion of fecal bile acids, in accordance with our observations that the hepatic cyp7a-1 mRNA expression was significantly elevated in response to APS. A further test with Western blotting also revealed that the APS stimulated cyp7a-1 protein expression. The effect on bile acid metabolism would support the conclusion that APS lowers blood cholesterol partly by increasing bile acid excretion. However, additional studies are required to further investigate the mechanism by which APS inhibits cholesterol absorption and increases bile acid excretion. Increased cholesterol synthesis by cholesterol absorption inhibitors has been reported in many previous studies. We observed for the first time that APS also increased cholesterol synthesis, different from that of statins. Cholesterol synthesis increases reciprocally to the reduction of absorption as a compensatory metabolic response, as indicated by an increase in the fecal excretion of neutral sterols and liver HMGCoA reductase activity in our study. It can be speculated that the increase in cholesterol synthesis is mainly due to de novo hepatic cholesterol. Although the reciprocal increase of cholesterol synthesis might have compromised partly the cholesterol lowering efficacy of the treatments, our data and many previous reports demonstrated plasma cholesterol was still significantly reduced. The results suggest that supplementation of APS for 3 months may be beneficial to liver health and function, which is supported by a significant decrease of ALT and AST and amelioration of liver fatty degeneration in hamsters under the experimental conditions. The expression of liver LDLR regulates plasma LDL-C homeostasis in both human and hamsters. Increased hepatic LDLR expression results in improved clearance of plasma LDL-C through receptor-mediated endocytosis. The activation of LDLR gene expression through depletion of intracellular cholesterol is the principal working mechanism of statins. In this study, we demonstrated that APS had strong activities in stimulating hepatic LDLR mRNA expression.

The local ethics committee that allowed us to perform liver biopsy only on a limited group of patients with clinical signs of impaired liver function at the enrolment in the trial. After NLCD, TGF-b serum concentration significantly decreased in CHC patients and not in NAFLD/NASH patients. To note, the TGF-b is not produced exclusively by the Treg cells, in fact, within inflammatory microenvironment, it is secreted by Kupffer cells and activated hepatic stellate cells, indicating that its reduction not necessarily to reflect the frequency of Treg cells, but rather the improving the hepatic condition. Moreover, CHC patients at the completion of the dietary regimen showed the same trend for the serum levels of HA. The down-regulation by the diet regimen of these two important validated biomarkers, for chronic liver inflammation, gains a statistical significance only in CHC patients, leading us to hypothesize that NLCD could have a potential improvement in the onset and progression of disease. Furthermore, these data are also in keeping with the lowering of systemic inflammation indices, such as high-sensitivity C reactive protein, after diet. Regarding the biochemical parameters, after 30 days of NLCD in both groups, we have not observed a reduction in body weight, in the concomitant BMI levels, and in homeostasis model assessment index, but rather a significant decrease in LDL cholesterol, with a tendency towards reduction in total cholesterol and triglyceride levels. These results reflect our intention of modulating only the lipid metabolism with a NLCD in both CHC and NAFLD/NASH patients. Further work in this area will no doubt yield insights into the impact of metabolic players on the shaping of the immune response. Many of the recent studies describe metabolic influence over T-cell fate and propose or included the initial evaluation of new molecular agonists and antagonists in animal models of autoimmune disease. In conclusion, this study suggests that a NLCD is able to regulate the Th17/Treg balance, by LXRs activation, reducing the risk of an adverse outcome LEE011 related to inflammation. A NLCD may result in a reduction in Th17 cells and recognized inflammatory complications of these cells in CHC including hepatic inflammation. Thus, our work supports the idea of a new approach in the management of chronic HCV-infected patients by changing lifestyle, promoting well-being and possibly hindering disease progression. Neonatal encephalopathy due to perinatal hypoxia-ischemia is an important cause of mortality and long-term neurological deficits such as cerebral palsy, seizures and mental retardation in babies born at term. However, therapeutic strategies for neonatal encephalopathy remain scarce. Hence, developing new treatment options for the newborn infant that effectively prevent or diminish the development of encephalopathy is of pivotal importance. Bone marrow-derived mesenchymal stem/stromal cells have been shown to promote tissue repair in various disease models ranging from cardiovascular to graft-versus-host disease.